– Ms. Levin is a seasoned CFO specializing in financing biotech companies with extensive expertise in accounting, investor relations, operations and strategy
– Dr. Porter has over 20 years of drug development expertise leading to successful NDA and sNDA product approvals for metabolic diseases
SAN DIEGO, January 19, 2022 /PRNewswire/ — ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to treat diseases with high unmet need, today announced the appointment of Alyssa Levin as Chief Financial Officer and addition of Lisa E. Porter, MD, to its Board of Directors.
“We are thrilled to welcome Alyssa and Lisa to ViaCyte to ensure we are well positioned for the future as we continue to advance breakthrough therapies for type 1 diabetes,” said Michael Yang, President and CEO, ViaCyte. “Alyssa’s commercial expertise will be a major asset as we execute our mission to realize the full potential of ViaCyte’s regenerative medicine platform, and our clinical programs will greatly benefit from Lisa’s first-hand experience as a physician and senior executive leading drug development strategy, clinical trials and commercialization.
“With important milestones on the horizon, I look forward to working with Michael and our leadership team as we chart the course for ViaCyte as an industry leader delivering potentially life-changing cell therapies,” said Ms. Levin. “I am excited to lead the finance team as we pursue significant clinical and growth opportunities to create increased value in our pipeline.”
“ViaCyte is leading the way in the clinic with new cell therapy approaches that will help reduce the burden of disease for people living with diabetes,” said Dr. Porter. “As a physician, I am excited to see ViaCyte expand the potential of cell replacement therapies for diabetes and other disease indications to bring functional cures to patients in need.”
Bios of named persons
Most recently, Ms. Levin served as Chief Financial Officer and Senior Vice President of Operations for Tentarix Biotherapeutics, where she led the company’s financial functions and played a key role in overseeing the company’s expansion. team as well as in the planning and implementation of operations. Previously, Ms. Levin was Chief Financial Officer of Bird Rock Bio, a clinical-stage biopharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases. In this role, she managed all finance, accounting, investor relations, treasury and human resources. Additionally, she has held positions at PwC LLP, Evomed LLC & Cosmederm Bioscience, Inc., and The Siegfried Group, LLP. Ms. Levin earned her BA from University of British Columbia and a master’s degree in professional accounting from the The University of Saskatchewan.
Dr. Porter currently serves as Chief Medical Officer for Nano Precision Medical, a biopharmaceutical company focused on drug delivery to treat chronic metabolic diseases, where she is responsible for the strategy, direction and execution of clinical development plans for new drug:device combinations. Prior to Nano Precision Medical, Dr. Porter was Medical Director for Eiger Biopharmaceuticals, Inc. and Dance Biopharma, Inc. (now Aerami Therapeutics). She previously held leadership positions at Amylin Pharmaceuticals, leading efforts that resulted in the approval of Bydureon, a GLP-1 agonist and the first weekly treatment for type 2 diabetes. In addition, Dr. Porter held several clinical development and leadership positions at GlaxoSmithKline Pharmaceuticals and Zeneca Pharmaceuticals. Dr. Porter, a graduate of the William and Mary College, obtained his medical degree from duke university medical school and completed his residency at duke university Medical Center, then completed a fellowship in endocrinology and hypertension at Brigham & Women’s Hospital.
ViaCyte is a private, clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: pluripotent stem cell-derived cell replacement therapies and medical device systems for encapsulation and implantation of cells. ViaCyte has the potential to use these technologies to treat critical human diseases and disorders that can potentially be treated by replacing lost or defective cells or proteins. The Company’s first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes to achieve goals of glycemic control and reduce the risk of hypoglycemia and diabetes-related complications. diabetes. To accelerate and expand ViaCyte’s efforts, it has established collaborative partnerships with leading companies, including CRISPR Therapeutics and WL Gore & Associates. ViaCyte is headquartered in San Diego, California. For more information, please visit www.viacyte.com and connect with ViaCyte on Twitter, Facebook, and LinkedIn.
Show original content to download multimedia:https://www.prnewswire.com/news-releases/viacyte-strengthens-management-team-with-appointment-of-alyssa-levin-as-chief-financial-officer-and-addition-of-lisa-porter- md-to-the-board-of-directors-301463612.html
SOURCE ViaCyte, Inc.